ATLANTA, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announced today that Rick Eiswirth, President and Chief Executive Officer, will present a corporate overview at the H.C. Wainwright 25th Annual Global Investment Conference. The conference is being held on September 11 – 13, 2023 at the Lotte New York Palace Hotel.
| Presentation Date: | Monday, September 11, 2023 |
| Time: | 11:30am ET |
Mr. Eiswirth and Mr. Russell Skibsted, Chief Financial Officer, will be available for one-on-one meetings with investors who are registered to attend the conference. To request a meeting and to register for the conference, please click here: https://hcwevents.com/annualconference/
About Alimera Sciences, Inc.
Alimera Sciences a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer. For more information, please visit: www.alimerasciences.com
| For investor inquiries: | For media inquiries: |
| Scott Gordon | Jules Abraham |
| for Alimera Sciences | for Alimera Sciences |
| This email address is being protected from spambots. You need JavaScript enabled to view it. | This email address is being protected from spambots. You need JavaScript enabled to view it. |
| Last Trade: | US$5.54 |
| Daily Volume: | 0 |
| Market Cap: | US$301.270M |
August 06, 2024 May 14, 2024 March 19, 2024 | |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORE
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
